| 1 |
Recruiting |
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
| Conditions: |
Neuroendocrine Tumors; Pancreatic Neuroendocrine Tumors |
| Intervention: |
|
|
| 2 |
Recruiting |
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
| Condition: |
Carcinoma, Neuroendocrine |
| Intervention: |
Other: Lu-DOTA-TATE radiopharmaceutical |
|
| 3 |
Not yet recruiting |
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
| Condition: |
Neuroendocrine Tumors |
| Intervention: |
Drug: Lutetium-177 Octreotate |
|
| 4 |
Recruiting |
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors
| Condition: |
Neuroendocrine Tumors |
| Interventions: |
Drug: Lanreotide (Autogel formulation); Drug: Placebo |
|
| 5 |
Recruiting |
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
| Condition: |
Advanced Cancer |
| Intervention: |
Biological: pembrolizumab |
|
| 6 |
Recruiting |
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
| Conditions: |
Cushing’s Disease,; Acromegaly,; Neuroendocrine Tumors,; Pituitary Tumors; Ectopic ACTH Secreting (EAS) Tumors,; Dumping Syndrome,; Prostate Cancer,; Melanoma Negative for bRAF,; Melanoma Negative for nRAS |
| Intervention: |
Drug: Pasireotide |
|
| 7 |
Recruiting |
Personalized PRRT of Neuroendocrine Tumors
| Conditions: |
Neuroendocrine Tumors; Carcinoid Tumor; Carcinoma, Neuroendocrine |
| Intervention: |
Drug: 177Lu-Octreotate |
|
| 8 |
Available |
18F-FDOPA PET in Neuroendocrine Tumours
| Conditions: |
Thyroid Cancer, Medullary; Carcinoid Tumor; Pheochromocytoma; Paraganglioma; Insulinoma; Neuroblastoma |
| Intervention: |
Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) |
|
| 9 |
Unknown † |
Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
| Conditions: |
Renal Cell Carcinoma; Neuroendocrine Tumours |
| Intervention: |
Drug: 18F-FAZA PET Imaging |
|
| 10 |
Unknown † |
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
| Conditions: |
Pheochromocytoma; Neuroblastoma; Paraganglioma; Medullary Thyroid Carcinoma; Carcinoid Tumors |
| Intervention: |
Drug: 123I-meta-iodobenzylguanidine |
|
| 11 |
Recruiting |
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors
| Condition: |
Neuroendocrine Tumors |
| Intervention: |
Other: Gallium-68 DOTA TATE PET scan |
|
| 12 |
Not yet recruiting |
An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis
| Condition: |
Carcinoma, Neuroendocrine |
| Intervention: |
Drug: Everolimus |
|
